PI3K/mTOR Pathway Biology in HR+ Breast Cancer

The phosphoinositide 3-kinase (PI3K)/AKT/mTOR signalling axis is among the most frequently dysregulated pathways in hormone receptor-positive (HR+), HER2-negative breast cancer, driving tumour cell survival, proliferation, and resistance to endocrine therapy. Class I PI3Ks are heterodimeric lipid kinases comprising a catalytic subunit (p110α, p110β, p110γ, or p110δ, encoded by PIK3CA, PIK3CB, PIK3CG, and PIK3CD respectively) paired with a regulatory subunit. Activating mutations in PIK3CA are detected in approximately 40% of HR+/HER2− breast cancers, making the p110α isoform a validated therapeutic target.

Downstream of PI3K, AKT phosphorylates numerous substrates that promote cell cycle progression, and mTORC1 drives cap-dependent translation of pro-growth proteins. mTORC2, often overlooked in earlier drug design, phosphorylates and fully activates AKT — creating a feedback loop that single-node inhibitors struggle to suppress completely. This biology underpins the rationale for dual PI3K/mTOR inhibition as a strategy to achieve more complete pathway blockade than either PI3K-selective or mTOR-selective agents alone.

Beyond PIK3CA mutations, PI3K pathway activation in HR+ breast cancer can arise from PTEN loss of function, activating mutations in PIK3R1 (the regulatory subunit), amplification of PIK3CA, and upstream receptor tyrosine kinase signalling. These non-PIK3CA mechanisms of pathway activation are precisely the scenarios where isoform-selective inhibitors — which target only p110α — are expected to have limited efficacy, and where pan-PI3K inhibitors may offer a meaningful clinical advantage. According to the National Cancer Institute, PI3K pathway alterations represent one of the most common druggable targets in solid tumours.

Why Pan-PI3K Inhibition Matters for PIK3CA Wild-Type Tumors

Pan-PI3K inhibition addresses the fundamental limitation of isoform-selective agents: tumours that activate the PI3K pathway through mechanisms other than PIK3CA mutation remain sensitive to broad PI3K blockade. In PIK3CA wild-type HR+/HER2− breast cancer, pathway activation frequently involves the p110β isoform (relevant in PTEN-deficient settings), p110δ (relevant in certain immune microenvironment contexts), or compensatory upregulation of non-α isoforms following selective p110α inhibition.

The dual inhibition of all four class I PI3K isoforms alongside mTORC1 and mTORC2 also addresses a well-characterised resistance mechanism: rapalog-mediated mTORC1 inhibition releases a negative feedback loop on PI3K, leading to AKT hyperactivation. By simultaneously suppressing PI3K and both mTOR complexes, gedatolisib interrupts this feedback and sustains more durable pathway suppression. This mechanism is supported by preclinical data from multiple research groups and is a key scientific rationale cited in the gedatolisib development programme.

“Pan-PI3K inhibitors like gedatolisib target all four class I PI3K isoforms and both mTOR complexes simultaneously — a mechanism designed to overcome the feedback resistance that limits isoform-selective and rapalog-based approaches in PIK3CA wild-type tumours.”

The clinical need is substantial. PIK3CA wild-type patients with HR+/HER2− advanced breast cancer who progress on CDK4/6 inhibitor plus endocrine therapy have limited targeted options. Fulvestrant, everolimus-based combinations, and chemotherapy represent the standard salvage landscape — none of which specifically addresses PI3K pathway activation in the wild-type setting. An approved pan-PI3K/mTOR inhibitor in this population would fill a recognised gap, as noted by regulatory bodies including the FDA in their guidance on molecularly defined breast cancer subgroups.

Gedatolisib: Compound Profile, Synonyms, and Development History

Gedatolisib is a potent, selective dual inhibitor of all four class I PI3K isoforms (PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ) and mTOR (both mTORC1 and mTORC2), originally developed by Pfizer. The compound is known in the scientific literature under multiple synonyms: PKI-587, PF-05212384, and WYE-687. Researchers conducting patent landscape analyses or literature searches must include all synonyms to ensure comprehensive retrieval across USPTO, EPO, and WIPO databases, as early filings and publications frequently use the development code rather than the INN.

Gedatolisib’s development originated within Pfizer’s oncology pipeline, where it advanced through Phase I and Phase II studies across multiple solid tumour indications. The compound’s dual PI3K/mTOR pharmacology was established in preclinical models and confirmed in early-phase clinical pharmacodynamic studies. The transition to a Celcuity-sponsored pivotal programme represents a strategic shift: Celcuity, a clinical-stage biopharmaceutical company focused on PI3K-driven cancers, has taken the lead in developing gedatolisib for the HR+/HER2− breast cancer indication, with Pfizer retaining a collaborative role.

For patent intelligence purposes, the compound’s development window spans approximately 2018–2025 for the most clinically relevant filings, though foundational composition-of-matter patents were filed earlier. Searches across EPO databases should incorporate all four synonyms — gedatolisib, PKI-587, PF-05212384, and WYE-687 — to ensure complete coverage of the assignee landscape and freedom-to-operate considerations.

The VIKTORIA-1 Trial and NDA Filing Signal

The VIKTORIA-1 trial is the pivotal clinical study that has generated the NDA filing signal for gedatolisib in HR+/HER2− advanced breast cancer, with particular interest in the PIK3CA wild-type subgroup. Sponsored by Celcuity in partnership with Pfizer, VIKTORIA-1 evaluates gedatolisib in combination with endocrine therapy in patients who have received prior CDK4/6 inhibitor-based treatment — the standard first-line regimen for HR+/HER2− advanced breast cancer.

The clinical significance of the PIK3CA wild-type subgroup analysis within VIKTORIA-1 is substantial. If gedatolisib demonstrates regulatory-grade efficacy in this population, it would represent the first approved PI3K pathway inhibitor specifically validated for PIK3CA wild-type HR+/HER2− breast cancer — a differentiated label that isoform-selective agents cannot claim. The NDA filing pathway signals that the trial data have met the evidentiary threshold required for regulatory submission, though final FDA review and approval decisions remain outstanding at the time of this analysis.

The combination strategy evaluated in VIKTORIA-1 — gedatolisib plus endocrine therapy — reflects the established clinical paradigm for HR+/HER2− advanced breast cancer, where PI3K pathway inhibitors have consistently demonstrated benefit when added to hormonal backbone therapy. The rationale for this combination is that endocrine therapy suppresses ER-driven proliferation while PI3K/mTOR inhibition addresses the bypass signalling that drives endocrine resistance, particularly in post-CDK4/6 inhibitor settings.

Competitive Modality Landscape: Selective vs. Pan-PI3K Inhibitors

The PI3K inhibitor landscape in HR+/HER2− breast cancer is defined by a fundamental mechanistic divide between isoform-selective and pan-PI3K agents. Alpelisib (Piqray, Novartis) is the reference isoform-selective PI3Kα inhibitor, approved by the FDA for PIK3CA-mutated HR+/HER2− advanced breast cancer in combination with fulvestrant. Its approval is explicitly restricted to PIK3CA-mutant patients, confirmed by the therascreen PIK3CA RGQ PCR Kit companion diagnostic. Inavolisib, another PI3Kα-selective inhibitor, has entered the competitive space with a distinct combination strategy.

Pan-PI3K inhibitors represent a distinct modality with a different patient selection logic. Rather than requiring a specific mutation for activity, pan-PI3K agents are designed to suppress the pathway regardless of the specific mechanism of activation. This broader mechanism comes with a corresponding toxicity consideration: inhibition of PI3Kδ and PI3Kγ, which play roles in immune cell signalling, can produce immunological adverse effects distinct from those of PI3Kα-selective agents. Hyperglycaemia, the class-defining toxicity of PI3Kα inhibitors (due to insulin signalling disruption), is less pronounced with pan-PI3K agents, though other tolerability considerations apply.

The competitive positioning of gedatolisib is therefore not head-to-head with alpelisib in the PIK3CA-mutant population, but rather complementary — addressing the approximately 60% of HR+/HER2− patients who are PIK3CA wild-type. This creates a potential biomarker-stratified market segmentation where isoform-selective and pan-PI3K inhibitors serve distinct, non-overlapping patient populations based on tumour molecular profiling. Regulatory bodies such as the EMA have increasingly emphasised biomarker-defined approval pathways for oncology agents, a framework that aligns with the VIKTORIA-1 subgroup analysis approach.

Patent Strategy and IP Considerations for Celcuity/Pfizer

The IP landscape for gedatolisib spans multiple patent families covering composition of matter, formulation, method of use, and combination therapy claims. Pfizer, as the originating company, holds foundational composition-of-matter patents on the gedatolisib molecular entity, filed under the development codes PKI-587 and PF-05212384. The transition of development leadership to Celcuity introduces additional IP considerations around method-of-use claims specific to the HR+/HER2− breast cancer indication, PIK3CA wild-type patient selection, and the combination with endocrine therapy backbones.

For freedom-to-operate and competitive intelligence analyses, the relevant patent search window spans 2018–2025, covering the period during which clinical indication-specific and combination claims are most likely to have been filed. Searches should be conducted across all major patent offices — USPTO, EPO, and WIPO — using all four compound synonyms (gedatolisib, PKI-587, PF-05212384, WYE-687) in combination with indication terms. PatSnap’s AI-native patent intelligence platform enables cross-database synonym searching with automated family clustering, reducing the risk of coverage gaps that arise from synonym proliferation in early-stage pharmaceutical patent filings.

Key IP questions for stakeholders in this space include: the expiry timeline for foundational composition-of-matter claims; the scope of method-of-use protection for the PIK3CA wild-type indication specifically; the extent to which the Celcuity/Pfizer collaboration agreement affects assignee rights on indication-specific filings; and whether biosimilar or generic entry timelines are affected by any patent term extensions associated with the NDA filing. These questions are addressable through systematic patent landscape analysis using PatSnap’s global patent database, which covers over 2 billion data points across 120+ countries.